In vivo and in vitro inhibition of pancreatic cancer growth by targeted alpha therapy using 213Bi-CHX.A″-C595

Cancer Biology and Therapy

Volumn 4, Issue 8, 2005, Pages 848-853

  Qu, Chang F ^a,b   Song, Yan J ^a,b   Rizvi, Syed M A ^a   Li, Yong ^a   Smith, Ross ^c,d   Perkins, Alan C ^e   Morgenstern, Alfred ^f   Brechbiel, Martin ^g   Allen, Barry J ^a,b  

^a ST GEORGE HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c ROYAL NORTH SHORE HOSPITAL   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

^e QUEEN S MEDICAL CENTRE   (United Kingdom)

^f JOINT RESEARCH CENTRE   (Italy)

^g NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Alpha particles; C595 monoclonal antibody; Cell cluster; MUC 1 mucin; Pancreatic cancer; Radioimmunotherapy

Indexed keywords

ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; CHELATING AGENT; CHELATOR CHX.A; MONOCLONAL ANTIBODY C595 BI 213; MUCIN 1; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CONTROL; CANCER GRAFT; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG CONJUGATION; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; METASTASIS; MOUSE; NICK END LABELING; NONHUMAN; PANCREAS CANCER; PROTEIN EXPRESSION; TARGET ORGAN; TARGETED ALPHA THERAPY; XENOGRAFT;

EID: 25144510993     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.4.8.1892     Document Type: Article

References (28)

1. Sener SF, Fremgen A, Menck HR, Winchester DP. Pancreatic cancer: A report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am College Surgeons 1999; 189:1-7.
2. Palazzo L, Roseau G, Chaussade S, Salmeron M, Gaudric M, Paolaggi JA. Annales de Chirurgie 1993; 47:419-24.
3. Goldenberg DM. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med 2002; 43:693-713.
4. Jurcic JG, Larson SM, Sgouros G, McDevitt MR, Finn RD, Divgi CR, et al. Targeted alpha particle immunotherapy for myeloid leukemia. Blood 2002; 100:1233-9.
5. McDevitt MR, Sgouros G, Finn RD, Humm JL, Jurcic JG, Larson SM, et al. Radioimmunotherapy with alpha-emitting nuclides. Eur J Nuclear Med 1998; 25:1341-51.
6. Allen BJ. Can alpha-immunotherapy succeed where other systemic modalities have failed? Nuclear Med Commun 1999; 20:205-7.
7. Kennel SJ, Boll R, Stabin M, Schuller HM, Mirzadeh S. Radioimmunotherapy of micro metastases in lung with vascular targeted 213Bi. Br J Cancer 1999; 80:175-84.
8. Allen B, Blagojevic N. Alpha and beta emitting radiolanthanides in targeted cancer therapy. Nucl Med Commun 1997; 20:205-7.
9. Li Y, Rizvi SM, Ranson M, Allen BJ. 213Bi-PAI2 conjugate selectively induces apoptosis in PC3 metastatic prostate cancer cell line and shows anti-cancer activity in a xenograft animal model. Br J Cancer 2002; 86:1197-203.
10. Price MR, Pugh JA, Hudecz F, Griffiths W, Jacobs E, Symonds IM, et al. C595 - a monoclonal antibody against the protein core of human urinary epithelial mucin commonly expressed in breast carcinomas. Br J Cancer. 1990; 61:681-6.
11. Baruch A, Hartmann M, Yoeli M, Adereth Y, Greenstein S, Stadler Y, et al. The breast cancer-associated MUC1 gene generates both a receptor and its cognate binding protein. Cancer Res 1999; 59:1552-61.
12. Qu CF, Li Y, Song YJ, Rizvi SM, Raja C, Zhang D, Samra J, Smith R, Perkins AC, Apostolidis C, Allen BJ. MUC1 expression in primary and metastatic pancreatic cancer cells for in vitro treatment by (213)Bi-C595 radioimmunoconjugate. Br J Cancer 2004; 91:2086-93.
13. Bardies M, Thedrez P, Gestin JF, Marcille BM, Guerreau D, FaivreChauvet A, et al. Use of multi-cell spheroids of ovarian carcinoma as an intraperitoneal radio-immunotherapy model: Uptake, retention kinetics and dosimetric evaluation. Int J Cancer 1992; 50:984-91.
14. 2: Relevance to efficacy of radiotherapy. Analyt Cellular Pathol 1989; 1:53-62.
15. Ballangrud AM, Yang WH, Charlton DE, McDevitt MR, Hamacher KA, Panageas KS, et al. Response of LNCaP spheroids after treatment with an alpha-particle emitter (213Bi)-labeled anti-prostate-specific membrane antigen antibody (J591). Cancer Res 2001; 61:2008-14.
16. Devys A, Thedrez P, Gautherot E, FaivreChauvet A, Sai-Maurel C, Rouvier E, et al. Comparative targeting of human colon-carcinoma multicell spheroids using one- and two-step (bispecific antibody) techniques. Int J Cancer 1996; 67:883-91.
17. Essand M, Gronvik C, Hartman T, Carlsson J. Radioimmunotherapy of prostatic adenocarcinomas: Effects of 131I-labelled E4 antibodies on cells at different depth in DU 145 spheroids. Int J Cancer 1995; 63:387-94.
18. Filippovich IV, Sorokina NI, Robillard N, Chatal JF. Radiation-induced apoptosis in human ovarian carcinoma cells growing as a monolayer and as multicell spheroids. Int J Cancer 1997; 72:851-9.
19. Ei Y, Tian Z, Rizvi S, Bander NH, Allen BJ. In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen. Prostate Cancer Prostatic Diseases 2002; 5:36-46.
20. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992; 119:493-501.
21. Gleave M, Hsieh JT, Gao CA, von Eschenbach AC, Chung EW. Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res 1991; 51:3753-61.
22. Satoh S, Hinoda Y, Hayashi T, Burdick MD, Imai K, Hollingsworth MA. Enhancement of metastatic properties of pancreatic cancer cells by MUC1 gene encoding an anti-adhesion molecule. Int J Cancer 2000; 88:507-18.
23. Marian Teresa Santini, Rainaldi G. Three-dimensional spheroid model in tumor biology. Pathbiology 1999; 67:148-57.
24. Scheinberg DA, Strand M, Gansow OA. Tumor imaging with radioactive metal chelates conjugated to monoclonal antibodies. Science 1982; 215:1511-3.
25. Vaughan AT, Bateman WJ, Fisher DR. The in vivo fate of a 211At labelled monoclonal antibody with known specificity in a murine system. International Journal of Radiation Oncol Biol Phy 1982; 8:1943-6.
26. McDevitt MR, Barendswaard E, Ma D, Lai L, Curcio MJ, Sgouros G, et al. An alpha-particle emitting antibody. Cancer Res 2000; 60:6095-100.
27. Macklis RM, Lin JY, Beresford B, Atcher RW, Hines JJ, Humm JL. Cellular kinetics, dosimetry, and radiobiology of alpha-particle radioimmunotherapy: Induction of apoptosis. Radiation Res 1992; 130:220-6.
28. Allen BJ, Li Y, Rizvi SM, Russell PJ. Targeted alpha therapy of prostate cancer. Methods in Mol Med 2003; 81:333-57.